|
|
Honey bee publish details |
| More
Information |
|
|
| Name |
|
|
|
| Address |
|
|
|
| District |
|
|
|
| State |
|
|
|
| Country |
|
|
|
| Category |
|
|
|
| Title |
First People’s Festival of Innovation November 19-29, 2022: Deep Tech Company’s profiles |
|
|
| Abstract |
|
|
|
| Details |
"Phloton: An Active Cooling, Portable, Easy To Use And Affordable Medicine Carrier
Company: Enhanced Innovations Private Limited
Email: Prerit@phloton.com
Founders: Prerit Mittal
Problem Addressed: Drug wastage in ice-based last-mile cold chains incurs high human and economic costs. In the Covid era, vaccine losses are estimated to touch USD
10 billion globally. This can be broadly attributed to three factors: insufficient cold chain capacity, lack of appropriate technology and, inadequate temperature monitoring. Critical drugs and diagnostic samples are transported using gel-packs or ice-boxes which are unreliable cold chain links for such temperature sensitive materials.
Technology: Our solution, Phloton is an active cooling, portable, easy to use and affordable medicine carrier. Phloton leverages solid state cooling – a proven technology, to ensure safe transportation of critical vaccines, drugs and diagnostic samples. The device uses IoT to relay temperature and geo- location data for monitoring and a Li-ion battery maintains requisite temperatures up to 16 hours. The device is also equipped with a solar panel for off-grid charging.
Societal Impact: Phloton intends to enhance last mile cold chain capacity for vaccine and drug delivery. Phloton can:
i) improve immunization coverage even in remotest geographies;
ii) safeguard vaccine potency by preventing freezing or warming of vaccine vials, iii) provide extra cold chain touchpoints to improve efficiencies, and iv) take the cold chain beyond vaccines / drugs to diagnostics.
Current Status: Laboratory prototype of Phloton developed and has undergone extensive testing under simulated test environments at the National Physical Laboratory (NPL) Commercial prototype is ready; Field trials will begin by beginning of 2023.
Company Website Link: www.phloton.com
Preeclampsia Detection, A Screening Test For All Pregnant Women
C ompany : Intignus Biote ch Private L imite d
Email: vaishnavikulkarni@intignusbiotech.com
Founders: Vaishnavi Kulkarni
Problem Addressed: P r e e c l a m psi a i s a leading cause of maternal and perinatal deaths and disabilities globally ; affecting more than 10 percent pregnancies. Diagnosis o f p r e e c l a m psi a h a p p e n s l a t e - post symptomatic m a n i f e s t a t i o n , threatening the life of both mother and child. Also, the available tests for diagnosis are resource intensive and expensive. As
preeclampsia can strike quickly, potentially causing severe and immediate complications unless the pregnancy is induced, early and point of care tests are needed.
Technology: We have developed PEscreen- a screening test for all pregnant women which can predict preeclampsia development in the upcoming weeks of gestation based on circulating levels of a placenta specific preeclampsia biomarker. This test is a sensitive, visual, semi-quantitative lateral flow assay that can help delineate moderate and high risk patients. The test is rapid, point-of-care and usable in low resource settings.
Societal Impact: 1. Reduce PE associated maternal deaths and fetal/neonatal deaths
2. Prevent PE-induced foetal growth retardation and facilitate birth of healthy babies
3. Improved healthcare quality in low resource settings
4. Especially in the rural settings, women’s health is capital as it lead to an increase in labor productivity.
5. Therefore, investments on health can help increase in incomes and subsequent increase in the wellbeing of the BoP population.
Current Status: Intignus Biotech’s PEscreen is under currently development and we will launch in 2023. ICMR is helping and handholding Intignus to develop the test technically. The Academic clinical study with PEscreen showed that the test has a sensitivity of 84.75%, specificity of 94.59%, and clinical accuracy of 93.41%.
Company Website Link: http://intignusbiotech.com/about-us/
AQM With Edge Computing & Cloud Analytics For Pharma & Life Science Applications
C o m p a n y : X e e e d I O P riva t e L imi t e d
Email: kanishka@xeeed.io
Founders: Kanishka Shah
Problem Addressed: Digitization is reshaping businesses, their product development, operating models, manufacturing processes, and requirement from healthcare providers and patients. To keep pace, enterprises are evolving to the next generation of Industry 4.0 by designing intelligent workflows using artificial intelligence (AI), data, analytics, cloud, and the Industrial Internet of Things (IIoT).
An IT and OT convergence must happen through new generation software and IoT enabled hardware if an enterprise has to transform digitally.
Technology: XEEED IO is a products & solution provider of integrated operations, security, health, and safety solutions and services. XEEED IO is trusted by customers across for innovative SaaS technology, seamless installation and integration, reliable maintenance, 24/7 monitoring, and insightful analytics. We’re guided by our vision of building safer, healthier, and more efficient environments for everyone.
Societal Impact: - Smart operations can save energy costs.
- Offering better security by constant surveillance
- Taking active action, such as alerting the local surveillance body in case of a security breach
- Remote monitoring of patients and providing medication for them
- Reminders of daily operation tasks such as payment of utility bills
- Introducing a collaborative work environment with no single point of failure.
Current Status: We have build our MVP of Hardware devices and Software Integration. We are working on pilot runs with multiple clients.
Company Website Link: www.xeeed.io
PoC Diagnostics For Microbial Infections
C o m p a ny : Mo d u l e Inno vat i o ns P v t . L t d
Email: sachin@moduleinnovations.com
Founders: Sachin Dubey, Usman Khan, & Jyoti Jog
Problem Addressed: With 1 in 3 women contracting UTI once in their lifetime, UTI are the second highest infection in the human body. However their treatment is still based on empirical antibiotic therapy since the current methods to detect UTI are time consuming, lab and labour intensive as well as in -accessible. This practice of empirical pill popping is leading to another pandemic of Anti Microbial Resistance.
Technology: Module Innovations USENSe is a simple and point of care test to detect UTI, by detecting the presence of bacteria in Urine. Based on the principle of vertical flow assay USENSe detects the presence of 4 major UTI bacteria namely E.coli, Klebsiella, Pseudomonas aeruginosa and Enterococci in a matter of just 15 minutes. It does not need a lab, instrument or a trained manpower to run.
Societal Impact: Due to lack of rapid and accessible tests to confirm UTI, doctors often prescribe broad spectrum empirical
antibiotics. However in upto 30% cases antibiotics were not needed. With USENSe the test will come closer to patients so that an evidence based decision be taken for treatment. Not only will this save them cost of unnecessary antibiotics but also help reduce the rise of AMR
Current Status: USENSe has been tested and validated with partner hospitals in Pune and Rajasthan. The test is now being prepared for regulatory submissions in India followed by regulatory approvals in the UK and US. Expected to hit the market in 2023 - Q3
Company Website Link: www.moduleinnovations.com
DC Based Solar Offgrid Refrigerator
Company: Devidayal Solar Solutions Pvt. Ltd.
Email: bizdev@ddsolar.in
Founders: Tushar Devidayal
Problem Addressed: Unreliable energy access limits the use of appliances and lack of affordable small-scale DRE-based cold storage solutions limiting adoption causes food spoilage.
Technology: Highly efficient Solar DC refrigerator with ideal PUF thickness and compressor configuration. All in one package, the system includes battery, panels, controller & remote monitoring system. The system can also incorporate lighting solutions, DC Fan and mobile charging. IoT enabled system
Societal Impact: DDSolar support low income generating households to improve their livelihood by providing cold storage solutions. DDSolar Refrigerator is used in Dairy, Fisheries, Fruit pulp, small restaurants & petty shops to generate incremental income for the beneficiaries. Our vision is Gender focussed, with currently 65% of our end users are women
Current Status: We are present in 12 states in India and 4 countries with more than 1000 solarsolutions sold. We are dedicated towards selling 50,000 units of Solar DC refrigerator by 2025.
Company Website Link: www.ddsolar.in
Diagnosis and Monitoring of Kidney Health with established non-invasive biomarkers
Company: Prantae Solutions Private Limited
Email: sumonakarjee@gmail.com
Founders: Sumona Karjee Mishra & Aseem Mishra
Problem Addressed: Chronic Kidney Disease (CKD) is one of the major global burdens with 110 million diagnosed cases in India and 694 million globally. It is often not associated with clinical symptoms during its initial progression and get identified at late stage where 70% damage has occurred to the kidney. Early diagnosis can help in reducing the number of CKD cases, unfortunately, reliable early diagnostics at Point of Care is unavailable.
Technology: Proflo-U is a patented platform technology comprises of battery operated mini-analyzer, nanomaterial biosensor-based test cartridge and a specially designed android app for data processing and result visualization. It is a simple 3-step process Add-Pour-Read, which gives the result within
3 minutes. Proflo-U can measure microalbumin, albumin, creatinine and ACR reliably with a press of a button. It can be used for detection and monitoring of kidney conditions.
Societal Impact: CKD is a real-world problem causing huge healthcare burden. According to the Ministry of Health and Family Welfare GoI, every year there is an addition of 0.2 million patients of ESKD requiring kidney transplantation whereas the annual figure of transplantation is just 6000. The dialysis facility is also not accessible to many and contributes to high DALY. Proflo-U through early-diagnosis and monitoring at PoC can reduce the burden.
Current Status: Proflo-U Platform has been commercialized and is available in market with the albumin measurement feature It will be upgraded for Creatinine and ACR measurement within next 6 months.
Company Website Link: www.proflou.com
A Safe Catheter Balloon Reprocessing System For Making Healthcare Affordable
Company: Incredible Devices Pvt Ltd Email: vikram@incredibledevices.in Founders: Vikram Goel & Rajwinder Kaur
P r o b l e m A d dr ess e d: Cardiovascular diseases treatment is very expensive and one of the main reasons is use of high-cost single use disposable devices (SUDs) such as catheters and balloons. Safe reprocessing of SUD is the biggest stumble block for making healthcare affordable. Seeking this, Incredible Devices focuses its research on development of technology for safe reprocessing of SUD
to make healthcare affordable.
Technology: Incredible Devices invention Catheter Reprocessing System (CRS) uses a patented process to clean catheters and balloons thereby making them safe for reuse and eventually decreasing the treatment cost.
Its Dynamic Fluid Cleaning process generates 74 times higher fluid pressure to remove biofilms. It generates mechanical vibration to remove surface diffused proteins. It also eliminates hospital-acquired-infection and spread of antimicrobial resistance bacteria. Biomedical waste generation has been reduced by 90% by reprocessing and reusing catheters and balloons with CRS.
Societal Impact: More than 9 lac patients and 50,000 medical workers benefitted, 11 states covered, 1250MT Carbon Footprint Reduced:
1. Affordable Healthcare for All
2. Reduce Antibiotic Dose: CRS reduces Hospital Acquired Infection, thus less antibiotic dose is required to treat patients. This avoid misuse of antibiotics.
3. Reduces generation of Biomedical Waste by 90%: Now 90% less catheters are required (less generation of hazardous medical waste).
4. Avoid Disease/Virus outbreak
5. Saving 90% Foreign Exchange
6. CRS promotes safe reuse, reduce carbon footprints and save water
Current Status: Technology has been commercialized across
11 states in India including 3 low income states. CRS is being used by leading Govt, Charitable and Private hospitals such as GMCH, PGI, SGPGI, KGMU etc, Narayana Hrudyalaya, GNDU Hospital etc and Fortis Group, Max Hospital, Medanta etc
Company Website Link: https://incredibledevices.in/
Bioresorbable medical devices (implants) based on polylactic acid
Company: Orthocrafts Innovations Pvt Ltd
Email: orthocrafts@gmail.com
Founders: Piyush V Joshi, Ashish Lele, & V Premnath
Problem Addressed: Bioresorbable implants are choice solutions amongst the surgeons and getting wide acceptance, however bioresorbable implants are too expensive, premium products are launched in India late and India is not a priority market for MNCs. This demands for a domestic manufacturer of bioresorbable implants to meet the requirements.
Technology: Orthocrafts has developed proprietary know-how for the synthesis of biomedical grade PLA. We have established a pilot scale facility having clean room spaces for the synthesis of biomedical grade PLA.
We have developed engineering know-how for the conversion of these polymers into bioresorbable implants such as interference screws, suture anchors and hernia tacks. Products have been evaluated extensively for mechanical performance, in-vitro biocompatibility and select in vivo biocompatibility tests.
ocietal Impact: With development of bioresorbable implants (interference screws, suture anchors and hernia tacks), Orthocrafts will assist Indian surgeons to treat their patients with choice solutions at affordable prices. The premium quality products will be made available in Indian market.
Current Status: Orthocrafts has developed bioresorbable implants, which have been evaluated to establish the substantial equivalence with predicate devices approved in India and will be launched in India upon CDSCO approval. We have obtained ISO 13485 QMS certification for our activities.
Company Website Link: www.orthocrafts.com
Serioss: An osteoconductive bone void filler Company: Serigen Mediproducts Pvt Ltd.
Email: anuya@serigenmed.com
Founders: Dr. Anuya Nisal, Dr. Swati Shukla, & Dr. Premnath Venugopalan
P r o b l e m Addressed: Large cavities of 3-5 cm in size can be formed in the bone either due to an accident, infection or cancer. The preferred method for filling these cavities today is a u t o g r a f t i n g .
Autografting involves taking bone from another location in the patients own body. Inspite of several limitations, autografting remains to be the gold standard as none of the synthetic materials match the performance of an autograft. Our product Serioss addresses this unmet need.
Technology: At Serigen, we have developed novel and innovative patent-protected processing protocols that convert silk threads into a solution that can be structured and shaped into a variety of different forms like blocks, pellets, films and microparticles with precise control on porosity and pore architecture, mechanical properties, degradation rates. These forms are nextgen solutions for tissue/ organ repair.
Societal Impact: The innovation has the potential to benefit various stakeholders
1. Patient - quality medical products at affordable price
2. Surgeon - accessibility to best-in-class medical devices with reduced post-surgical complications
3. Silk farmers - strengthen the hands of poor Indian silk farmers
4. Demonstrate successful commercialisation of deeptech indigenous products through women-led entrepreneurship
Current Status: Serigen has recently completed a clinical trial for demonstrating safe use of Serioss in bone repair and is now gearing up for a pivotal clinical trial. The product would be launched in the Indian market in 2024 followed by a global launch.
Company Website Link: https://serigenmed.com
ZeBox: A cutting-edge air decontamination technology
Company: Biomoneta Research Pvt. Ltd.
Email: janani@biomoneta.com
Founders: Janani Venkatraman & Arindam Ghatak
Problem Addressed: Airborne microbes pose a considerable threat to human life and business. 14-24% of Hospital acquired infections involve transmission via air and over 4 million people die of respiratory infections every year. Many of these infections are drug resistant or have poor treatment options.
Biomoneta creates solutions to prevent the spread of airborne infections in hospitals and in homes, and to prevent product contamination in critical R&D and manufacturing environments.
Technology: Biomoneta’s flagship product, the ZeBox, is a cutting-edge air decontamination technology.
Innovated in India for the world, and validated by Indian and Global agencies, the ZeBox has demonstrated effectiveness in the real world, such as in ICUs, OPDs, procedure rooms, home care etc. ZeBox devices can be used safely in human presence with zero downtime and low lifetime maintenance.
Societal Impact: The WHO states that HAIs are the most frequent adverse event in healthcare delivery worldwide.
Over 95% of ICUs and NICUs in India are multi-patient with no downtime for terminal cleaning. The ZeBox, which requires minimal staff intervention or sophisticated infrastructure, can support infection control in a range of healthcare situations - corporate hospitals, hospitals in Tier II / Tier III cities, rural healthcare centres, home care etc.
Current Status: ZeBox Mini (CE certified) and ZeBox Mid devices, servicing areas of 200 and 600 sq ft, respectively, are available in the market. Devices are sold directly by the company and via distributors. The technology is covered by granted patents.
Company Website Link: www.biomoneta.com
A platform for methane bioconversion that enables the creation of carbon friendly products
Company: String Bio Private Limited
Email: rajeshwari@stringbio.com
Founders: Dr. Ezhil Subbian & Vinod Kumar
Problem Addressed: By 2050, the world would have to feed 10Bn people and cut down on GHG emissions to slow the impact of climate change. The world is facing its biggest challenge yet, of accelerating food production sustainability while balancing climate goals alongside. String Bio is leveraging biotechnology to solve the problem of sustainable food production with decarbonization opportunities, helping create a circular value chain from GHG as a resource.
Technology: String Bio’s patent protected platform for methane bioconversion enables the creation of carbon friendly products using GHG as raw material. String Bio provides a range of environment-friendly solutions for human nutrition, animal nutrition and valuable crop inputs which not only increase yield & productivity but also are a step towards fighting the crisis of climate change.
Societal Impact: By harnessing sustainable use cases from GHG we will not only decrease the carbon footprint but reuse it to secure food for all. Methane based biostimulants and proteins provide a sustainable commercial ready solution to increase crop yield and animal health, paving the way for better ROI to farmers and consumers at the same time benefiting the environment.
Current Status: String Bio currently offers sustainable solutions for crop improvement & nutrition, human nutrition, animal nutrition and cosmetics.
Company Website Link: https://www.stringbio.com/
Development of Conformationally Restricted Cationic Peptides as Antimicrobial Agents Against Multidrug Resistant Bacteria
Company: Biotide Solutions LLP
Email: biotidesolutions@gmail.com
Founders: Prof. V.S. Chauhan & Dr. Nitin Yadav
Problem Addressed: Antimicrobial resistance is one of the most serious heath challenges. To address this, we have designed and synthesized novel synthetic 11-residue cationic peptides with inherent propensity to acquire helical structure.
Testing against a panel of gram-positive and gram-negative bacteria including drug resistant strains in the laboratory and in CROs showed that the selective peptides are highly efficacious. These peptides are stable to proteolysis with acceptable range of toxicity and therefore are excellent candidates for further development.
Technology: The newly developed conformational cationic peptides are excellent candidates for further development as drugs against stubborn bacterial infections. We found that these peptides act by multiple pathways and therefore there are less chances of bacteria acquiring resistance to them. These peptides can be developed for both intravenous and topical applications. There is a great paucity of new generation of antimicrobial agents but the resistance problem needs to be attended urgently.
Societal Impact: Antimicrobial infections particularly with multidrug resistance bacteria is one of the most serious health problems in India. A large number of deaths occur because of the most of the currently in use antibiotics have become ineffective and almost untreatable. Any new development in this field by the way of novel drugs will be of immense value not only in the health system but also for the society at large.
Current Status: These peptides can easily be made at gram scale. All experiments to show their efficacy, toxicity, stability have been completed. The next translation phase to take these peptides for clinical development should begin urgently.
Company Website Link:
Developing Innovative, affordable, and accessible therapies to tackle antimicrobial resistance and cancer
Company: Bugworks Research India Pvt. Ltd.
Email: bala@bugworksresearch.com
Founders: Dr Anand AnandKumar / Dr Santanu Datta / Dr V. Balasubramanian
Problem Addressed: BUGWORKS is a clinical stage pharmaceutical company that harnesses the power of science to develop innovative, affordable, accessible therapies to tackle two major health threats with high unmet need and significant impact on humanity - antimicrobial resistance and cancer. Our pipeline consists of differentiated, proprietary targeted small molecules for treating a plethora of multidrug-resistant bacterial infections including biothreat pathogens and hypoxic, immunosuppressed, refractory and hard-to-treat solid tumours.
Technology: BWC0977 is a novel dual-targeting drug with excellent activity against a broad-spectrum of MDR pathogens implicated in serious hospital and community acquired infections including a spectrum of biothreat pathogens. Currently, BWC0977 is undergoing first-in-human trials in healthy volunteers in Australia.
In immuno-oncology space, we are developing affordable, differentiated, small molecule therapeutics for treating highly hypoxic tumors where adenosine plays a pivotal role in creating an immunosuppressive and tumor-promoting environment.
Societal Impact: In 2019, AMR and cancer together claimed
15 millions lives with a disproportionate number of deaths in LMICs. BWC0977 has the potential to fill a five-decade void in antibiotic pipeline. The high cost of cancer therapy has a huge impact on access in LMICs and our novel class of adenosine receptor antagonists is aimed as an affordable and accessible therapeutic modality for the treatment of hard- to-treat solid tumours.
Current Status: BWC0977 - a novel class of antibiotic is undergoing first-in-human studies to establish safety and tolerability in healthy volunteers in Australia. A diverse portfolio of immuno-oncology projects is in advanced preclinical stage of discovery and development.
Company Website Link: https://bugworksresearch.com
Rena: An Affordable Retrofit Air Cleaner Company: Swachh.io (Sauve AT Pvt Ltd) Email: Karan@swachh.io
Founders: Karan Rao
Problem Addressed: Air Pollution due to particulates has caused millions of deaths worldwide and it impacts the economically weaker section the most. Furthermore, the associated spread of air borne pathogens and allergens is a matter of grave concern.
Technology: Rena is a retrofit filter that can be attached to most ceiling fans, which then converts the fan into an air purifier. There are two modes for winter and summer, so that there is less circulation in the winter and no loss in circulation in the summer.
The filters are biodegradable and do not produce any long lasting waste.
Societal Impact: There is a large underserved segment that cannot afford Rs. 10,000 filters. And even for the middle income group, replacing the conventional air filters is expensive. Rena provides an affordable solution for households and schools.
Current Status: Rena is being manufactured and is only currently sold directly to high risk segments like schools.
Public launch will be soon for mass market. Presently at TRL 8
Company Website Link: Https://Swachh.io
An affordable seed sowing machine for small and marginal farmers
Company: Balasore Agro Private Limited
Email: balasoreagro@gmail.com
Founders: Manoranjan Das Adhikari
Problem Addressed: Presently the small and poor farmers are sowing the seeds manually by which no line and space is being maintained, which lead to huge production loss (of crops). The farmers are facing financial losses due to the high investment and less income with this conventional method. By utilizing our machine, the production of the crop will be more and at time same time the farmer can save the cultivation cost, thus increasing their livelihood.
Technology: The weight of the machine is 16kg. The capacity is 1 Acre land sowing within 4 hour. Seed chamber holding capacity - 3Kg of Seeds.
Row to row distance adjustable.
Seed to seed gap adjustable. Depth of the seed adjustable.
Societal Impact: It increase the livelyhood of poor and marginal farmers.
Current Status: We have sold 5000 units of the machine to small and marginal farmers.
Company Website Link: balasoreagro.com
Ease: Safe, Personalized, Holistic Mental Healthcare Company: StimVeda Neurosciences Private Limited
Email: ramya@stimveda.com
Founders: Ramya YS & Lakshay Sahni
Problem Addressed: 56 million Indians suffer from Depression, and our healthcare system is overburdened with only 0.3 psychiatrists per 100,000 people.
Despite advances in the understanding of psychopharmacology, only ~60% patients r e s p o n d t o antidepressants. These medications also take a long time to show effect and also present adverse side-effects (Emotional
flattening, gastrointestinal issues, cognitive fog, etc.).
There is a need for adjunctive intervention that can work on the physiological as well as behavioural aspect of the brain and support faster recovery.
Technology: Ease is a portable brain stimulation and monitoring headband with a digital cognitive therapy application for depression treatment and management (being built in collaboration with AIIMS Delhi).
When your brain is stimulated, your brain has the potential to absorb and adapt to activities better. The stimulation helps increase the probability of neuronal firing in the cognitive, emotion and default mode networks of the brain, via DLPFC. EEG helps track brain activity, and will help arrive at hybrid depression scores. This is combined with our Digital CET.
Societal Impact: For Mental Health professionals:
a. Need for alternative/additional treatment as the burden of the illness is high
b. Data-driven tech that will empower them with objective measurement vs. just relying on a patient’s experiences
c. Reducing the burden on the OPD
For Patients:
a. Safe, no adverse side effects
b. Reduced cost of treatment
c. Reduced recovery time
Current Status: Our compact prototype with miniaturised electronics, comfortable mechanical design, and our Digital CET application is ready. We are now going for a multicenter clinical study.
We are also backed by the BIG grant, and marquee VCs: Capital 2B (InfoEdge, Temasek), Whiteboard Capital, and prestigious incubators across the country.
Company Website Link: www.stimveda.com
" |
|
|
| Volume No. |
Honey Bee, 33(3-4)40-47, 2022 |
|
|
| Sout |
|
|
|
| Call Number |
|
|
 
|
|
